Top Medical News
Secukinumab yields sustained positive effects on molecular, histopathologic psoriasis markers
22 hours ago
Treatment with secukinumab leads to sustained clinical response among patients with psoriasis, with clinical response being associated with rapid and persistent normalization of keratin 16 (K16) and inflammatory gene expression for most patients, according to data from the ObePso-S study.
Lovastatin cream shows therapeutic potential in disseminated superficial actinic porokeratosis
3 days ago
In the treatment of patients with disseminated superficial actinic porokeratosis (DSAP), the use of topical lovastatin 2% cream may help improve outcomes, with the addition of cholesterol having a limited benefit, according to a study.
Promising treatment options for chronic hives on the horizon
Jairia Dela Cruz, 4 days ago
Dupilumab, barzolvolimab, and remibrutinib appear to help reduce disease activity in patients with chronic spontaneous urticaria, according to the results of three studies presented at AAAAI 2023.
PCSK9 inhibition tied to decreased psoriasis risk
Jairia Dela Cruz, 20 Mar 2023
Inhibition of the proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway appears to be causally associated with a lower risk of psoriasis, regardless of the concentration levels of circulating low-density lipoprotein (LDL), according a two-sample Mendelian randomization study.
Long-term OLE boosts potential of remibrutinib for CSU
Audrey Abella, 20 Mar 2023
In the 52-week open-label extension (OLE) of a phase IIb study presented at AAAAI 2023, the BTK* inhibitor remibrutinib demonstrated sustained efficacy and a favourable safety profile for the treatment of chronic spontaneous urticaria (CSU).
Which factors predict progression from discoid lupus to severe SLE?
14 Mar 2023
A diagnosis of discoid lupus erythematosus (DLE) at age 25 years or below, phototype V to VI, and antinuclear antibody titers of ≥1:320 are significantly associated with the development of severe systemic lupus erythematosus (SLE), according to a study.
Neoadjuvant–adjuvant bests adjuvant-only pembrolizumab in advanced melanoma
14 Mar 2023
For patients with stage III or IV melanoma, treatment with pembrolizumab both before and after surgical resection leads to longer event-free survival than treatment with pembrolizumab only after the procedure, according to the results of a phase II study.
Special Reports
Expert consensus: Patient profile should guide antihistamine choice in primary care setting
10 Dec 2019
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
Antihistamine therapy for allergic rhinitis and urticaria: An Asia-Pacific perspective
01 Nov 2018
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
Improving Medical Practice through Advancement in Clinical Treatment: IMPACT Aesthetics & Suturing Workshop 2018
Dr. Steven Ang, Dr. Leo Kah Woon, 11 Jul 2018
DCH Auriga recently held their first Aesthetics and Suturing Workshop under the IMPACT continuing medical education series – a scientific platform that aims to cascade the latest updates on disease management and share best clinical practices among healthcare professionals in Singapore. Two experts on aesthetics and aesthetic surgery shared their insights on suturing techniques and current approaches for scar prevention and management.
Conference Reports
Skin biomarkers predict AD risk, severity in newborns
Elvira Manzano, 27 Oct 2022
Predicting which newborn will go on to develop atopic dermatitis (AD) and how severe it will be is now feasible, according to the BABY* study.
Ruxolitinib improves repigmentation in vitiligo through 52 weeks
Elaine Soliven, 21 Oct 2022
Long-term use of ruxolitinib cream continued to improve facial and total body repigmentation in patients with nonsegmental vitiligo from 24 to 52 weeks, according to an updated pooled analysis of the phase III TRuE-V1* and TRuE-V2** studies presented at EADV 2022.
Dupilumab reduces itch, improves skin lesions in prurigo nodularis
Elvira Manzano, 20 Oct 2022
Dupilumab improves itch response and skin lesions in patients with prurigo nodularis (PN) inadequately controlled with prior therapies in the LIBERTY-PN PRIME trial.
Lebrikizumab efficacy in atopic dermatitis maintained at 1 year
Roshini Claire Anthony, 12 Oct 2022

Maintenance lebrikizumab monotherapy appears to improve outcomes in patients with moderate-to-severe atopic dermatitis (AD), according to results of the phase III ADvocate1 and ADvocate2 trials.

Ligelizumab safe, effective in patients with chronic spontaneous urticaria
Elaine Soliven, 06 Oct 2022
Ligelizumab, a next-generation anti-IgE antibody, is safe and effective in treating patients with H1-antihistamine (H1-AH) refractory chronic spontaneous urticaria (CSU), according to two phase III studies presented at EADV 2022.
Deucravacitinib bestows benefits in Asian patients with plaque psoriasis
Roshini Claire Anthony, 04 Oct 2022

The benefit of deucravacitinib in moderate to severe plaque psoriasis was demonstrated in a population of Asian patients, according to results of the phase III POETYK PSO-3 trial.

Rocatinlimab a new treatment option for head and neck AD?
Audrey Abella, 23 Sep 2022
Rocatinlimab improved disease severity in patients with moderate-to-severe head and neck atopic dermatitis (H&N AD), a post hoc analysis of a phase IIb trial has shown.